On September 16, 2022 Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, reported that Chief Executive Officer James G. Cullem will deliver a corporate update and host investor 1×1 meetings at the Ladenburg Thalmann Healthcare Conference in New York, NY (Press release, Allarity Therapeutics, SEP 16, 2022, View Source [SID1234619618]). Mr. Cullem’s presentation is scheduled for Thursday, September 29, 2022 at 3:00 p.m. ET at the Sofitel Hotel New York at Track 2 – St. Germain III.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in meeting with Allarity Therapeutics should contact their Ladenburg Thalmann representative or email the Company at [email protected].

A webcast of the presentation will be available at the following link: https://bit.ly/3qDK5Kt. In addition, the webcast will be available on the investor section of the Allarity website, and will be archived for 30 days following the conference.